Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00383370 | Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD | PHASE1 | COMPLETED | 20 | — | — | Oct 1, 2006 | Jul 1, 2008 | Apr 21, 2011 | 6 | United States |
| Arm | Type | Description |
|---|---|---|
| ITV-1 | EXPERIMENTAL | VEGF Trap formulation 1 |
| ITV-2 | EXPERIMENTAL | VEGF Trap formulation 2 |
| ITV-2 OL | EXPERIMENTAL | VEGF Trap formulation 2 open label, higher concentration |
| Name | Type | Description |
|---|---|---|
| VEGF Trap | DRUG | VEGF Trap formulation 1, ITV-1 |
Inclusion Criteria: * Subfoveal CNV secondary to AMD. * Central retinal (including lesion) thickness ≥ 250 µm as measured by OCT. * ETDRS best-corrected visual acuity (BCVA) of 20/40 to 20/400 (73 to 20 letters) Exclusion Criteria: * No prior treatment with the following in the study eye: * Su...